The ProSense® Cryoablation System:

A new hope in breast care

ProSense® is a liquid nitrogen (LN2) based cryoablation system with a powerful, compact, and user-friendly design for maximum efficacy in breast tumor destruction. 

How does
it work?

IceCure’s ProSense Cryoablation System utilizes liquid nitrogen to generate ultra-cold temperatures quickly to create large lethal zones for maximum efficacy in tumor destruction.

Guided by CT or ultrasound, a cryoprobe is inserted into the tumor. A freeze-thaw-freeze cycle destroys the targeted tissue, which becomes necrotic debris eventually absorbed by the body over time – without the need to excise the tumor.


Clinically proven

Cost effective in-office treatment

Short treatment time for fibroadenomas –
only 5-15 minutes

Touch-screen console

Choice of probes for
customized treatment

(small disposable

Low pressure, safe,
convenient and easy to

Painless with immediate return to daily activities

FDA cleared
and CE marked


ICE3 is the largest controlled multilocation clinical trial ever performed for liquid nitrogen (LN2) based cryoablation of small, low-risk, early-stage malignant breast tumors without subsequently removing them. The trial began in 2014 and has completed recruitment of 206 patients in 19 hospitals and medical centers across the US, including Columbia University Medical Center and Mount Sinai Beth Israel. 


The ProSense™ system is considered an optimal solution for treating breast tumors.


ProSense is FDA-cleared and has successfully been treating fibroadenomas since clinical trials began in 2012.


“The FDA has approved the use of cryoablation as a safe and effective therapy for fibroadenomas.” 

American Society of Breast Surgeon’s (ASBrS) Consensus Statement for Management of Fibroadenomas of the Breast

ICE3 Trial 

ICE3 is the largest controlled multilocation clinical trial ever performed for nitrogen-based cryoablation of small, low-risk, early stage malignant breast tumors without subsequently removing them.


of trial participants did not have recurrence as of interim analysis performed in July 2022. 


 “Cryoablation offers an exciting, minimally invasive option to open surgery in the treatment of small, early-stage breast cancer tumors. The innovative Liquid Nitrogen (LN2) based ProSense® System provides more efficient, targeted treatment to completely destroy the tumor in a quick, office-based procedure”

Professor Eisuke Fukuma, MD, PhD, Chairman of Breast Center, Kameda Medical Center, Japan 

Dr. Belinda Barlcay-White,
Breast radiologist,
on breast tumor cryoablation